You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 7,819,796


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,819,796
Title:Embryo modification and implantation
Abstract: The present invention relates to constructs and methods used to enhance the attachment and implantation of an embryo. It is shown that modified glycolipids and glycolipid-attachment molecule constructs can be used to modify embryos, or localised to target tissues, to enhance interaction between the embryo and the target tissue, (typically the endometrium). The invention may advantageously be used to enhance implantation of embryos in the uterus, for example, in IVF treatments.
Inventor(s): Blake; Deborah A. (Auckland, NZ), Carter; Nicola L. (Auckland, NZ), Henry; Stephen M. (Howick, NZ)
Assignee: Kode Biotech Limited (Auckland, NZ)
Application Number:10/510,377
Patent Claims:1. A method of enhancing the implantation of an embryo into the endometrium of an animal including the steps: a. modifying the embryo to incorporate a glycolipid-attachment molecule construct; and b. transferring the modified embryo to the uterus of the animal; where a glycolipid is exogenously modified to incorporate a binding part adapted to enable the modified glycolipid to bind the attachment molecule.

2. A method as claimed in claim 1 where the modified glycolipid is bound to an attachment molecule modified to incorporate a binding part adapted to enable the modified attachment molecule to bind to the modified glycolipid either indirectly through a bridging molecule or directly.

3. A method as claimed in claim 2 where the modification to the glycolipid is to the carbohydrate portion of the glycolipid.

4. A method as claimed in claim 2 wherein the attachment molecule is selected from the group consisting of: natural or synthetic carbohydrates or oligosaccharides; glycolipids; glycoconjugates; proteins or peptides; acyl groups; and polymers.

5. A method as claimed in claim 4 where the attachment molecule is selected from the group consisting of: poly L-lysine; antibodies; lectins; polyvinyl pyrrolidine; and functionally equivalent derivatives thereof.

6. A method as claimed in claim 5 wherein the attachment molecule is an immunoglobulin.

7. A method as claimed in claim 6 wherein the attachment molecule is immunoglobulin G (IgG).

8. A method as claimed in claim 2 where the attachment molecule is adapted to interact with the epithelial cells of the endometrium, mucus, mucin, or other endogenous or exogenously provided component of mucus.

9. A method as claimed in claim 8 where the attachment molecule is an endometrial attachment molecule.

10. A method as claimed in claim 2 where the glycolipid is selected from the group consisting of phosphoglycerides and sphingolipids.

11. A method as claimed in claim 2 where the attachment molecule and the glycolipid are bound together by simple non-covalent binding interactions including ionic, van de Waals, water exclusion, electrostatic, hydrogen bonding and chelation binding.

12. A method as claimed in claim 2 where the attachment molecule and the glycolipid are bound together by covalent bonding.

13. A method as claimed in claim 2 where the attachment molecule and the glycolipid are bound together by avidin-biotin binding.

14. A method as claimed in claim 13 where the binding part of the glycolipid comprises biotin and the binding part of the attachment molecule comprises avidin.

15. A method as claimed in claim 13 where the binding part of the glycolipid comprises avidin and the binding part of the attachment molecule comprises biotin.

16. A method as claimed in claim 13 where the attachment molecules and the glycolipid are bound together through a bridging molecule.

17. A method as claimed in claim 16 where the bridging molecule comprises avidin and the binding part of both the attachment molecule and the glycolipid comprises biotin.

18. A method as claimed in claim 16 wherein the bridging molecule comprises biotin and the binding part of both the attachment molecule and the glycolipid comprises avidin.

19. A method as claimed in claim 2 where the attachment molecule and the glycolipid are bound together by a chelation interation between at least one chelator and a chelated metal ion.

20. A method as claimed in claim 19 wherein the binding part of both the attachment molecule and the glycolipid comprises a chelator.

21. A method as claimed in claim 19 wherein the chelator is a poly-histidine recombinant protein.

22. A method as claimed in claim 19 where the chelator is attached covalently to the glycolipid.

23. A method as claimed in claim 19 where the chelator is attached non-covalently to the glycolipid.

24. A method as claimed in claim 23 wherein the chelator is attached to the glycolipid via biotin or avidin.

25. A method as claimed in claim 23 where the chelated metal ion is Co.sup.2+, Ni.sup.2+ or Cu.sup.2+.

26. A method as claimed in claim 2 where the glycolipid modified to incorporate a binding part is a biotinylated glycolipid.

27. A method as claimed in claim 2 where the glycolipid of the ganglioside class that contains sialic acid groups, or a glycolipid of the neutral class that contains galactose.

28. A method as claimed in claim 2 where the attachment molecule is a molecule that has a binding affinity for molecules on cell membranes including the mucus coat of cell membranes.

29. A method as claimed in claim 28 wherein the molecules on cell membranes are receptor sites and/or blood group related antigens.

30. A method as claimed in claim 29 where the cell membranes are endometrial.

31. A method as claimed in claim 1 where the animal is a human or domesticated animal.

32. A method as ,claimed in claim 1 where the modified embryo is prepared from a species, hybrid or variety of animal different from the species, hybrid or variety of animal of the uterus.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.